
|Videos|November 22, 2016
The Future of Biomarkers in Prostate Cancer
Author(s)Mark Stein, MD
Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the future of biomarkers in prostate cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































